Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 |
| clinicaltrials |
| NCT05303467 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM(FRONTIER) | recruiting | Phase 1 | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07145112 | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | recruiting | Phase 1 | 25 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | recruiting | Phase 3 | 150 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07195591 | Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care(BRIDGES) | recruiting | Phase 3 | 766 | GT Medical Technologies, Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04115761 | Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients | recruiting | Phase 2 | 24 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06389591 | RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) | recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06558214 | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial(OPTIMUS PRIME) | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | recruiting | Phase 2 | 52 | Inova Health Care ServicesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831772 | REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma(REMIND) | recruiting | N/A | 4 | University of MinnesotaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07089641 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | recruiting | Phase 1 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06816927 | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab(GIANT) | recruiting | Phase 2 | 92 | Duke UniversityOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06797661 | Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.(NVUCVR) | recruiting | N/A | 40 | Erasme University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05052957 | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)(hSTAR GBM) | recruiting | Phase 2 | 16 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07452458 | Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma | recruiting | Phase 3 | 398 | NRG OncologyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05139056 | Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06410248 | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | recruiting | Phase 1 | 22 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06613841 | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma(GBM) | recruiting | Early Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06934889 | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06989086 | FearLess in NeuroOncology | recruiting | N/A | 112 | Virginia Commonwealth UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05839379 | Targeted Pediatric High-Grade Glioma Therapy | recruiting | — | 350 | Nationwide Children's HospitalOTHER | 7 | Sep 8, 2026 | clinicaltrials |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06894225 | Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature | recruiting | Phase 2 | 12 | National Neuroscience InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07356973 | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma(OPTICAL) | recruiting | Phase 2 | 147 | CRISM Therapeutics LTDINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07384884 | Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas(SLITT-GBM) | recruiting | N/A | 12 | King's College Hospital NHS TrustOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | recruiting | Phase 3 | 408 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT07409584 | Mental Health and Suicidality in Glioblastoma Patients in Germany(SHINE-GLIO) | recruiting | — | 180 | University Hospital, EssenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | recruiting | Phase 2 | 256 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma | recruiting | Early Phase 1 | 8 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials